SAFETY AND HEALTH POLICY CONSIDERATIONS RELATED TO THE USE OF BUPRENORPHINE/NALOXONE AS AN OFFICE-BASED TREATMENT FOR OPIATE DEPENDENCE
I tiakina i:
BRIDGE, T.P., ET AL., SAFETY AND HEALTH POLICY CONSIDERATIONS RELATED TO THE USE OF BUPRENORPHINE/NALOXONE AS AN OFFICE-BASED TREATMENT FOR OPIATE DEPENDENCE. DRUG AND ALCOHOL DEPENDENCE, Vol. 70, no. 2 SUPL. (2003), p. S79-S85.
Ref.
121194
Tauwāhi:
SIIS R.854 Archivo
Palabras clave:
Antagonistas, Buprenorfina, Crítica, Drogodependencias, Fármacos, Heroína, Programas de desintoxicación, Programas de mantenimiento, Seguridad, Servicios de salud
Antagonistas, Buprenorfina, Crítica, Drogodependencias, Fármacos, Heroína, Programas de desintoxicación, Programas de mantenimiento, Seguridad, Servicios de salud
Ngā tūemi rite: SAFETY AND HEALTH POLICY CONSIDERATIONS RELATED TO THE USE OF BUPRENORPHINE/NALOXONE AS AN OFFICE-BASED TREATMENT FOR OPIATE DEPENDENCE
- PHARMACOKINETICS OF THE COMBINATION TABLET OF BUPRENORPHINE AND NALOXONE
- CLINICAL AND PHARMACOLOGICAL EVALUATION OF BUPRENORPHINE AND NALOXONE COMBINATIONS: WHY THE 4:1 RATIO FOR TREATMENT?
- BUPRENORPHINE FOR OFFICE-BASED TREATMENT OF OPIATE DEPENDENCE: US AND INTERNATIONAL FIELD EXPERIENCE
- THE CLINICAL PHARMACOLOGY OF BUPRENORPHINE: EXTRAPOLATING FROM THE LABORATORY TO THE CLINIC
- NATIONAL CLINIC GUIDELINES AND PROCEDURES FOR THE USE OF BUPRENORPHINE IN THE TREATMENT OF HEROIN DEPENDENCE
- USE OF BUPRENORPHINE IN PREGNANCY: PATIENT MANAGEMENT AND EFFECTS ON THE NEONATE